Skip to main content
Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma

Fig. 3

IRF-1 as a predictive marker for anti-PD-1 therapy. a IRF-1 expression by best objective radiographic response (ORR) (Mean +/- Std Dev) b) PD-L1 by ORR (Mean +/- SD). c Progression-free survival from the start of therapy stratified by IRF-1 expression level) d) Progression-free survival from the start of therapy stratified by PD-L1 expression level

Back to article page